Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract discusses the exclusion of cardiovascular and cerebrovascular disease patients from hair transplantation candidates and highlights the potential challenge of obtaining detailed medical histories in busy clinical settings, without reporting new results.

This study found that nanoparticles did not permeate intact rat skin but could penetrate skin that had been artificially punctured, primarily through grooves or hair follicles.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This source outlines the potential effects of treatments commonly used in trichology on SARS-CoV-2 infection and offers a guide for managing trichological patients during the COVID-19 era, addressing the challenges of safely visiting and treating patients.

Parents often claim to use more home safety measures than they actually do.

In this randomized, placebo-controlled study, Kūlaris supplementation significantly improved quality of life for participants with mild-to-severe acne over 12 weeks, though no significant changes in general skin health measures were observed compared to placebo.

This study reported that anti-androgens combined with lifestyle modifications were more effective than metformin and lifestyle in reducing hirsutism and certain hormonal measures in women with PCOS, but they were not more effective than a placebo combined with lifestyle changes.

In this study, the researchers evaluated the quality of 20 commercial dog shampoos in Mexico City, finding pH variations and non-compliance with labeling regulations, but all products met other quality standards, assisting veterinarians in product recommendation and informing dog owners about product safety and value.

This study found that ablative fractional carbon dioxide laser treatment improved skin fibrosis, reduced skin hardening, and enhanced hair follicle growth in localized scleroderma patients, with significant improvements across several clinical measures and no severe adverse effects observed.

This study found that the new cytopurine/pentadecanoic glyceride topical solution significantly improved total hair count and reduced daily hair shedding in patients with androgenetic alopecia over 16 weeks, although other measures did not differ from placebo.

In this study, two formulations of platelet-rich plasma and two mesotherapy products showed varying degrees of effectiveness in improving hair thickness, density, and count in androgenetic alopecia patients after six months, with MZT1 and PRP2 achieving statistically significant improvements in most measures.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study discusses the transformative potential of gene editing technologies, such as CRISPR-Cas9, for personalized aesthetic interventions in dermatology, but highlights the need for rigorous safety measures, ethical considerations, and careful regulatory oversight before clinical application.

This study found no significant evidence supporting the effectiveness of platelet-rich plasma injections for treating mild-to-moderate erectile dysfunction compared to placebo.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

This study reported that a single treatment using macrofocused ultrasound energy with a 2 mm transducer significantly reduced pore count, pore volume, and pore index in 34 Thai subjects with enlarged facial pores over a 6-month period, with no adverse events observed.

This study evaluated the effectiveness and safety of a cinchonine nanostructured lipid carrier serum for hair growth in mouse models, finding that it significantly increased hair length and enhanced follicle penetration compared to controls, with no notable irritation observed.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

This study found that isolated scalp microneedling did not improve scalp coverage or hair density in male pattern hair loss patients, with no adverse events reported.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this study, powdered milk samples from Senegal showed varying levels of heavy metals, with some exceeding acceptable maximum levels for calcium, potassium, and phosphorus, indicating potential safety concerns.

This study observed that baricitinib led to significant hair regrowth and improved psychological well-being in severe alopecia areata patients over 48 weeks, with 63.2% achieving a SALT score of ≤20.

This study observed that JAK inhibitors were safe and effective for patients with moderate-to-severe alopecia areata and comorbid latent hepatitis B or stable tuberculosis, with careful monitoring and selective prophylaxis.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This real-world study found that baricitinib 4 mg daily was effective in promoting hair regrowth and improving psychological well-being in Italian adults with severe alopecia areata over 48 weeks, with 63.2% of patients achieving significant hair recovery and 9.4% experiencing adverse events.